title: PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells.
abstract: Exposure to genotoxic agents, such as irradiation produces DNA damage, the toxicity of which is augmented when the DNA repair is impaired. Poly (ADP-ribose) polymerase (PARP) inhibitors were found to be "synthetic lethal" in cells deficient in BRCA1 and BRCA2 that impair homologous recombination. However, since many tumors, including prostate cancer (PCa) rarely have on such mutations, there is considerable interest in finding alternative determinants of PARP inhibitor sensitivity. We evaluated the effectiveness of radiation in combination with the PARP inhibitor, rucaparib in PCa cells. The combination index for clonogenic survival following radiation and rucaparib treatments revealed synergistic interactions in a panel of PCa cell lines, being strongest for LNCaP and VCaP cells that express ETS gene fusion proteins. These findings correlated with synergistic interactions for senescence activation, as indicated by β--galactosidase staining. Absence of PTEN and presence of ETS gene fusion thus facilitated activation of senescence, which contributed to decreased clonogenic survival. Increased radiosensitivity in the presence of rucaparib was associated with persistent DNA breaks, as determined by χ-H2AX, p53BP1, and Rad51 foci. VCaP cells, which harbor the TMPRSS2-ERG gene fusion and PC3 cells that stably express a similar construct (fusion III) showed enhanced sensitivity towards rucaparib, which, in turn, increased the radiation response to a similar extent as the DNA-PKcs inhibitor NU7441. Rucaparib radiosensitized PCa cells, with a clear benefit of low dose-rate radiation (LDR) administered over a longer period of time that caused enhanced DNA damage. LDR mimicking brachytherapy, which is used successfully in the clinic, was most effective when combined with rucaparib by inducing persistent DNA damage and senescence, leading to decreased clonogenic survival. This combination was most effective in the presence of the TMPRSS2-ERG and in the absence of PTEN, indicating clinical potential for brachytherapy in patients with intermediate and high risk PCa.
authors.affiliation: Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
authors.forename: Payel
authors.initials: P
authors.lastname: Chatterjee
authors.forename: Gaurav S
authors.initials: GS
authors.lastname: Choudhary
authors.forename: Arishya
authors.initials: A
authors.lastname: Sharma
authors.forename: Kamini
authors.initials: K
authors.lastname: Singh
authors.forename: Warren D
authors.initials: WD
authors.lastname: Heston
authors.forename: Jay
authors.initials: J
authors.lastname: Ciezki
authors.forename: Eric A
authors.initials: EA
authors.lastname: Klein
authors.forename: Alexandru
authors.initials: A
authors.lastname: Almasan
mesh_terms: D002460:Cell Line; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects / Q000528:radiation effects; D016922:Cellular Senescence / Q000187:drug effects / Q000528:radiation effects; D002867:Chromones / Q000494:pharmacology; D005455:Fluorescent Antibody Technique; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D008297:Male; D009025:Morpholines / Q000494:pharmacology; D051059:PTEN Phosphohydrolase / Q000235:genetics / Q000378:metabolism*; D011065:Poly(ADP-ribose) Polymerases / Q000235:genetics / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000378:metabolism*; D011993:Recombinant Fusion Proteins; D012697:Serine Endopeptidases; D015534:Trans-Activators; D000071230:Transcriptional Regulator ERG
chemical_list: C499693:8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one; D002867:Chromones; C072312:ERG protein, human; D007211:Indoles; D009025:Morpholines; D011993:Recombinant Fusion Proteins; D015534:Trans-Activators; D000071230:Transcriptional Regulator ERG; C531549:rucaparib; D011065:Poly(ADP-ribose) Polymerases; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human; D012697:Serine Endopeptidases; C421305:TMPRSS2 protein, human
references.citation: Nature. 2012 Jan 18;481(7381):287-94
references.pmid: 22258607
references.citation: Cancer Cell. 2011 May 17;19(5):664-78
references.pmid: 21575865
references.citation: Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1179-85
references.pmid: 22494583
references.citation: Cell Cycle. 2012 Oct 15;11(20):3837-50
references.pmid: 22983061
references.citation: Cell. 2008 May 2;133(3):403-14
references.pmid: 18455982
references.citation: Radiother Oncol. 2008 Aug;88(2):258-68
references.pmid: 18456354
references.citation: Cell Cycle. 2011 Oct 15;10(20):3598-607
references.pmid: 22030621
references.citation: Prostate. 2011 Oct 1;71(14):1548-58
references.pmid: 21394739
references.citation: J Clin Oncol. 2011 Sep 20;29(27):3659-68
references.pmid: 21859993
references.citation: Nat Rev Cancer. 2010 Apr;10(4):293-301
references.pmid: 20200537
references.citation: Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):410-9
references.pmid: 14751510
references.citation: Autophagy. 2012 Feb 1;8(2):236-51
references.pmid: 22240589
references.citation: Nat Genet. 2009 May;41(5):619-24
references.pmid: 19396168
references.citation: Oncogene. 2012 Jan 12;31(2):251-64
references.pmid: 21706052
references.citation: Apoptosis. 2005 Dec;10(6):1411-8
references.pmid: 16215673
references.citation: N Engl J Med. 2009 Jul 9;361(2):123-34
references.pmid: 19553641
references.citation: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references.pmid: 22237781
references.citation: Nat Rev Cancer. 2012 Dec;12(12):801-17
references.pmid: 23175119
references.citation: Br J Cancer. 2011 Oct 11;105(8):1114-22
references.pmid: 21989215
references.citation: Clin Cancer Res. 2008 Dec 1;14(23):7917-23
references.pmid: 19047122
references.citation: Biochem J. 2011 Jun 15;436(3):671-9
references.pmid: 21434873
references.citation: Cancer Res. 2011 Apr 1;71(7):2632-42
references.pmid: 21300766
references.citation: Clin Cancer Res. 2012 Feb 15;18(4):1015-27
references.pmid: 22114138
references.citation: Semin Urol Oncol. 2000 May;18(2):133-6
references.pmid: 10875454
references.citation: J Natl Cancer Inst. 2011 Feb 16;103(4):334-46
references.pmid: 21183737
references.citation: Mol Cell Biol. 2007 May;27(9):3511-20
references.pmid: 17325036
references.citation: Nature. 2005 Apr 14;434(7035):913-7
references.pmid: 15829966
references.citation: Cancer Res. 2004 Jul 1;64(13):4390-3
references.pmid: 15231644
references.citation: Science. 1990 Feb 9;247(4943):712-5
references.pmid: 2300823
references.citation: Oncogene. 2008 Sep 11;27(40):5348-53
references.pmid: 18542058
references.citation: Methods Mol Biol. 2012;920:613-26
references.pmid: 22941631
references.citation: Mol Cancer Ther. 2011 Dec;10(12):2320-9
references.pmid: 21926192
references.citation: Clin Cancer Res. 2007 May 15;13(10):3033-42
references.pmid: 17505006
references.citation: Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1198-204
references.pmid: 21470790
references.citation: Mol Cancer Ther. 2011 Jul;10(7):1185-93
references.pmid: 21571912
references.citation: Cancer Discov. 2012 Dec;2(12):1134-49
references.pmid: 22993403
references.citation: Mol Cancer Ther. 2007 Apr;6(4):1368-78
references.pmid: 17431115
references.citation: Mol Cancer Ther. 2010 Jun;9(6):1775-87
references.pmid: 20530711
references.citation: Oncogene. 2007 Mar 22;26(13):1897-909
references.pmid: 17043659
references.citation: J Cell Biol. 2008 Dec 29;183(7):1203-12
references.pmid: 19103807
references.citation: Cancer Res. 2008 Oct 15;68(20):8516-24
references.pmid: 18922926
references.citation: BJOG. 2011 Mar;118(4):429-32
references.pmid: 21244617
references.citation: Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3406-11
references.pmid: 21300883
references.citation: PLoS One. 2011;6(6):e21319
references.pmid: 21731703
references.citation: Mol Cancer Ther. 2010 Feb;9(2):347-57
references.pmid: 20124459
references.citation: Cell. 2010 Apr 16;141(2):243-54
references.pmid: 20362325